Equities Analysts Offer Predictions for Insulet Q3 Earnings

Insulet Co. (NASDAQ:PODD) – Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for shares of Insulet in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings of $0.75 per share for the quarter, down from their previous forecast of $0.93. The consensus estimate for Insulet’s current full-year earnings is $3.04 per share. Leerink Partnrs also issued estimates for Insulet’s Q4 2024 earnings at $1.00 EPS and FY2025 earnings at $4.48 EPS.

Other research analysts also recently issued reports about the company. Citigroup increased their price objective on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. UBS Group raised their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. BTIG Research increased their target price on shares of Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Canaccord Genuity Group boosted their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler lifted their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $242.29.

Insulet Price Performance

PODD stock opened at $236.59 on Friday. The stock has a market cap of $16.59 billion, a PE ratio of 43.02, a price-to-earnings-growth ratio of 4.35 and a beta of 1.21. The stock has a 50-day moving average price of $218.20 and a two-hundred day moving average price of $196.82. Insulet has a 1 year low of $128.68 and a 1 year high of $243.98. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same period in the previous year, the firm posted $0.38 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in PODD. SageView Advisory Group LLC bought a new stake in shares of Insulet during the 4th quarter worth about $236,000. PNC Financial Services Group Inc. grew its position in shares of Insulet by 37.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,479 shares of the medical instruments supplier’s stock valued at $2,274,000 after purchasing an additional 2,856 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Insulet by 42.9% during the first quarter. GAMMA Investing LLC now owns 360 shares of the medical instruments supplier’s stock worth $62,000 after purchasing an additional 108 shares during the period. Mather Group LLC. bought a new position in shares of Insulet during the first quarter worth approximately $53,000. Finally, Banque Cantonale Vaudoise lifted its holdings in Insulet by 79.1% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,614 shares of the medical instruments supplier’s stock worth $1,305,000 after purchasing an additional 3,362 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.